Abstract: The present invention relates to fusion proteins targeted to the central nervous system (CNS) and its use for the treatment of lysosomal storage disorders (LSD).

Abstract: The present invention provides variants of human ?-Glucocerebrosidase protein.

Abstract: The present invention provides apo crystals and co-crystals of insulin-degrading enzyme (IDE) and their uses in drug development.

Abstract: The present invention relates to co-crystals of Liver X receptor beta ligand binding domain (LXR?-LBD) with agonists and to the three-dimensional X-ray crystal structures derived thereof.

Abstract: The present invention provides apo crystals and co-crystals of insulin-degrading enzyme (IDE) and their uses in drug development.

Abstract: The present invention relates to crystal forms of mammalian OSC and the crystal structure information obtained from them, to methods of preparing such crystal forms, and to their use for the identification and/or design of inhibitors of OSC activity. A further subject matter of the invention are methods for the identification and/or design of inhibitor compounds of OSC activity, the inhibitor compounds of OSC activity identified by these methods and their use in pharmaceutical compositions for the treatment and/or prevention of diseases which are associated with OSC comprising hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections and gallstones, and/or treatment and/or prophylaxis of impaired glucose tolerance, diabetes, tumors and/or hyperproliferative disorders, preferably for the treatment and/or prophylaxis of hypercholesterolemia and/or hyperlipemia.

Abstract: The present invention provides a crystal of the extracellular domain of mammalian DPP-IV, wherein the crystal has an orthorhombic space group of P212121 and one homodimer of DPP-IV in the asymmetric unit. Also provided is a co-crystal which includes a ligand bound to the active site of mammalian DPP-IV. The invention permits the identification or design of inhibitor compounds of DPP-IV activity, for use in treatment of type II diabetes.

Abstract: The present invention provides crystals of carnitine palmitoyltransferase (CPT) and co-crystals of CPT with an inhibitor compounds that allow screening for novel inhibitors of CPT-2 by determining the structure of co-crystals based on the coordinates of the crystals disclosed herein.

Abstract: The present invention provides a crystal of the extracellular domain of mammalian DPP-IV, wherein the crystal has an orthorhombic space group of P212121 and one homodimer of DPP-IV in the asymmetric unit. Also provided is a co-crystal which includes a ligand bound to the active site of mammalian DPP-IV. The invention permits the identification or design of inhibitor compounds of DPP-IV activity, for use in treatment of type II diabetes.

Abstract: The present invention relates to crystal forms of mammmalian OSC and the crystal structure information obtained from them, to methods of preparing such crystal forms, and to their use for the identification and/or design of inhibitors of OSC activity. A further subject matter of the invention are methods for the identification and/or design of inhibitor compounds of OSC activity, the inhibitor compounds of OSC activity identified by these methods and their use in pharmaceutical compositions for the treatment and/or prevention of diseases which are associated with OSC comprising hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections and gallstones, and/or treatment and/or prophylaxis of impaired glucose tolerance, diabetes, tumors and/or hyperproliferative disorders, preferably for the treatment and/or prophylaxis of hypercholesterolemia and/or hyperlipemia.